Amarin's days could be numbered after a positive adcom vote.
The Canadian marijuana cultivator's fiscal second-quarter report sent shares sharply lower Thursday morning.
Did investors overreact to Catalyst's third-quarter earnings report?
Here's where a de-risked Amarin could be headed over the next few months.
Investors were none too happy with the cancer specialist's Q3 results last month.
BioMarin and Sarepta Therapeutics should be top growth plays in the next decade.
Amgen's shares posted stellar gains last month. Can this blue chip biotech stock keep churning higher?
Is Bristol's stock still an attractive buy after last month's uptick?
Investors didn't get what they wanted from Amarin's report, but better days could be close at hand.
Can the stock march even higher after its recent rally?
This under-the-radar marijuana company could be the industry's lodestar in the coming decade.
AstraZeneca's stock has crushed its closest peers over the past three years. Can it keep heading higher?
Acadia's shares shrugged off a stronger-than-expected Q3 earnings report yesterday.
These titans of the healthcare sector sport virtual monopolies in their core markets.
Is this small-cap biotech stock a bad-news buy?
BioMarin's stock is poised for big gains in 2020. Here's why.
Investors weren't impressed with the drugmaker's Q3 report. Should bargain hunters take advantage of this recent weakness in its shares?
Biogen's risk-to-reward ratio may now be too compelling to pass up.
Biogen's shares are getting a boost from a pair of catalysts this morning.
After this online pet retailer's second-quarter earnings lit a fire underneath its shares yesterday, can it continue to bound higher?